News >

Novel Ruxolitinib Approaches Explored in Myelofibrosis

Angelica Welch
Published: Monday, Sep 17, 2018

Robyn M. Scherber, MD, MPH

Robyn M. Scherber, MD, MPH

Researchers are exploring combination approaches with ruxolitinib (Jakafi) in myelofibrosis as a potential strategy for reinvigorating the drug’s effect in patients who progress, relapse, or become intolerant on single-agent treatment with the JAK inhibitor.

In her concluding remarks, Scherber stressed that, when treating a patient with myelofibrosis who is becoming refractory or resistant to ruxolitinib, it is important to first maximize the JAK inhibitor. Additionally, she emphasized that it is important to monitor symptoms and keep an eye on the patient’s quality of life.   

References

  1. Masarova L, Cortes J, Pemmaraju N, Daver N. Phase 2 study of ruxolitinib in combination with 5-azacitidine in patients with myelofibrosis. J Clin Oncol. 2017;35(15):7063.
  2. Mesa RA, Yao X, Cripe LC, et al. Lenalidomide and prednisone for myelofibrosis: Easten Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood. 2010;116(22):4436-4438.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x